| Literature DB >> 36232139 |
Jin-Jhe Wang1,2, Chien-Hsiung Lai1,2,3,4, Ting-Yu Kuo5, Meng-Hung Lin5, Yao-Hsu Yang4,5,6, Chau-Yin Chen1,2.
Abstract
Obesity has been regarded as a risk factor for several ocular diseases. This study aims to investigate the age- and sex-specific relationship between epiblepharon and obesity in children. A retrospective case-control study was conducted using the Chang Gung Research Database. Children ≤ 18 years of age with epiblepharon were identified from 1 January 2009 to 31 December 2019. Children were classified into three groups: normal, overweight and obese groups. A total of 513 patients and 1026 controls (57.7% males) aged 1 to 18 matched by sex and age were included in the analysis. The median body mass index (BMI) of children with epiblepharon was significantly higher than that of children without epiblepharon (p < 0.001). In the subgroup analysis, among boys aged 4 to 9 years, the BMI in boys with epiblepharon was significantly higher than that in boys without epiblepharon (p < 0.05) and the risk of epiblepahron in overweight/obese boys was significantly higher than in non-overweight boys (OR = 1.74, 95% CI = 1.07-2.82 for age 4 to 6; OR = 3.06, 95% CI = 1.56-6.03 for age 7 to 9). On the other hand, among girls aged 13 to 18 years, the BMI in adolescent girls with epiblepharon was significantly higher than that in the control group (p < 0.05) and overweight/obese girls had a statistically higher risk of persistent epiblepharon than non-overweight girls (OR = 3.70, 95% CI = 1.38-9.97). The association between obesity and epiblepharon varies in strength according to age in a sex-specific manner.Entities:
Keywords: body mass index; epiblepharon; obesity; overweight; sex-specific difference
Mesh:
Year: 2022 PMID: 36232139 PMCID: PMC9566480 DOI: 10.3390/ijerph191912839
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Flowchart of the study population selection.
Demographic characteristics of patients.
| Characteristic | Epiblepharon | Control | |
|---|---|---|---|
| Sex, | 1.000 | ||
| Female | 217 (42.3) | 434 (42.3) | |
| Male | 296 (57.7) | 592 (57.7) | |
| Age, years | |||
| Mean ± SD (range) | 6.28 ± 3.66 (1–18) | 6.28 ± 3.66 (1–18) | 1.000 |
| Age at baseline, years | 1.000 | ||
| 1–3 | 126 (24.6%) | 252 (24.6%) | |
| 4–6 | 191 (37.2%) | 382 (37.2%) | |
| 7–9 | 99 (19.3%) | 198 (19.3%) | |
| 10–12 | 55 (10.7%) | 110 (10.7%) | |
| 13–18 | 42 (8.2%) | 84 (8.2%) | |
| BMI classification | <0.001 | ||
| Normal | 307 (59.8%) | 746 (72.7%) | |
| Overweight | 83 (16.2%) | 126 (12.3%) | |
| Obese | 123 (24.0%) | 154 (15.0%) | |
| BMI, median (Q1–Q3) | 17.0 (15.5–19.4) | 16.3 (15.0–18.1) | <0.001 |
The association between epiblepharon and body mass index (BMI) by sex and age.
| Age (y) | Epiblepharon | Male | Female | ||||
|---|---|---|---|---|---|---|---|
| No. | BMI, Median (Q1–Q3) | No. | BMI, Median (Q1–Q3) | ||||
| 1–3 | Yes | 82 | 16.7 (15.6–17.3) | 0.195 | 44 | 16.5 (15.6–17.4) | 0.034 |
| No | 164 | 16.3 (15.5–17.4) | 88 | 15.9 (14.8–17.2) | |||
| 4–6 | Yes | 107 | 16.2 (15.1–18.1) | 0.012 | 84 | 15.6 (14.4–17.6) | 0.366 |
| No | 214 | 15.7 (14.8–17.0) | 168 | 15.6 (14.6–16.8) | |||
| 7–9 | Yes | 54 | 18.9 (15.8–23.2) | 0.001 | 45 | 16.8 (15.4–19.1) | 0.169 |
| No | 108 | 16.4 (14.9–18.4) | 90 | 16.0 (14.8–18.4) | |||
| 10–12 | Yes | 37 | 20.7 (17.3–22.9) | 0.289 | 18 | 18.7 (16.4–21.0) | 0.060 |
| No | 74 | 19.0 (16.3–21.9) | 36 | 16.8 (14.8–18.6) | |||
| 13–18 | Yes | 16 | 25.1 (21.4–28.4) | 0.045 | 26 | 23.2 (19.5–27.2) | 0.008 |
| No | 32 | 21.3 (19.8–24.9) | 52 | 19.5 (17.3–22.5) | |||
Figure 2Comparison of body mass index (BMI) between epiblepharon and control groups (boys’ group). The background chart is the BMI-for-age growth curves by percentile, based on 2013 Taiwan standards.
Figure 3Comparison of body mass index (BMI) between epiblepharon and control groups (girls’ group). The background chart is the BMI-for-age growth curves by percentile, based on 2013 Taiwan standards.
Odds ratios (OR) between epiblepharon and overweight/obesity by sex and age.
| Age (y) | Overweight/ | Male | Female | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Epiblepharon | Control | Epiblepharon | Control | ||||||||
| N (%) | N (%) | OR | 95% CI | N (%) | N (%) | OR | 95% CI | ||||
| 1–3 | Yes | 21 (25.6) | 38 (23.2) | 1.14 | 0.62–2.11 | 0.673 | 15 (34.1) | 21 (23.9) | 1.65 | 0.75–3.65 | 0.216 |
| No | 61 (74.4) | 126 (76.8) | 29 (65.9) | 67 (76.1) | |||||||
| 4–6 | Yes | 45 (42.1) | 63 (29.4) | 1.74 | 1.07–2.82 | 0.025 | 30 (35.7) | 38 (22.6) | 1.90 | 1.07–3.38 | 0.028 |
| No | 62 (57.9) | 151 (70.6) | 54 (64.3) | 130 (77.4) | |||||||
| 7–9 | Yes | 31 (57.4) | 33 (30.6) | 3.06 | 1.56–6.03 | 0.001 | 14 (31.1) | 24 (26.7) | 1.24 | 0.57–2.72 | 0.589 |
| No | 23 (42.6) | 75 (69.4) | 31 (68.9) | 66 (73.3) | |||||||
| 10–12 | Yes | 18 (48.7) | 29 (39.2) | 1.47 | 0.66–3.26 | 0.343 | 7 (38.9) | 6 (16.7) | 3.18 | 0.88–11.56 | 0.079 |
| No | 19 (51.4) | 45 (60.8) | 11 (61.1) | 30 (83.3) | |||||||
| 13–18 | Yes | 10 (62.5) | 14 (43.8) | 2.14 | 0.63–7.33 | 0.225 | 15 (57.7) | 14 (26.9) | 3.70 | 1.38–9.97 | 0.010 |
| No | 6 (37.5) | 18 (56.3) | 11 (42.3) | 38 (73.1) | |||||||